Business EconomyPosted at: Jan 23 2025 6:33PM


Labs of Dr Reddy reports a 2 percent rise in its Q3FY25 net profit

Hyderabad, Jan 23 (UNI) Dr. Reddy’s Laboratories Ltd on Thursday reported a 2 percent year-on-year increase in its consolidated net profit to Rs 1,413 crore for the quarter ended December 31, 2024, as against Rs 1,379 crore in the year-ago period.
Hyderabad-based pharma giant's revenue from operations during the quarter stood at Rs 8,358.6 crore which was 16 percent up over Rs 7,215 crore in the corresponding period in the previous year.
The profit after tax (PAT) is attributable to the equity holders of the company, the pharma company said in a release here.
However, for 9MFY25, the consolidated net profit declined 5 percent year-on-year to Rs 4,060.6 crore.
The growth was largely driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, revenues from India and Emerging Markets.
Company's Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for the reported quarter stood at Rs 2,298 crore which is 27.5 percent of the company's revenues.
While segment-wise revenue, the Company's Global Generics business accounted for Rs Rs 7,375 crore in revenue which was 17 percent higher than Rs 6,309 crore reported year-ago.
The Growth was largely driven by revenues from the acquired NRT portfolio, higher volumes, and new product launches.
The Pharmaceutical Services and Active (PSAI) segment contributed Rs 822 crore which was up from Rs 784 crore in Q3FY24, registering a 5 percent uptick.
In India, Q3FY25 revenues at Rs 1,350 crore, YoY growth of 14 percent, and QoQ decline of 4 percent.
The growth was led by revenues from the in-licensed vaccine portfolio, new product launches as well as price increases, partially offset by lower volume pick-up in certain brands in Cardiac and Gastrointestinal therapy areas.
Emerging markets: Q3FY25 revenues at Rs 1,440 crore, recording a YoY growth of 12 percent and flat QoQ. YoY growth is attributable to market share expansion as well as new product launches.
Commenting on the results, Co-Chairman & MD, G V Prasad said: “We delivered double-digit growth aided by our newly acquired NRT business, new launches, and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability, and innovation.”
UNI KNR BD
Please log in to get detailed story.
Tags: #Labs of Dr Reddy reports a 2 percent rise in its Q3FY25 net profit
More News

Markets end flat as global uncertainty weighs

09 Jul 2025 | 6:53 PM

Mumbai, July 9 (UNI) Indian equity markets moved in a tight range today as global uncertainty and tariff tensions weighed in on investor sentiment.

see more..

Meta announces its stake in Ray Ban’s parent firm

09 Jul 2025 | 6:44 PM

New Delhi, July 9 (UNI) In a strategic collaborative move, Meta Platforms Inc., or Meta, takes a minority stake in Ray Ban’s parent organization, EssilorLuxottica.

see more..

Kottayam-Kochi rubber market rates

09 Jul 2025 | 6:38 PM

Kottayam, July 9 (UNI) Following were the market rates of rubber per quintal announced by the Rubber Board here today.

see more..

ClearTax unveils AI Assistant in 7 languages

09 Jul 2025 | 6:00 PM

Bengaluru, July 9 (UNI) In a major step toward inclusive digital taxation, fintech platform Clear today announced the nationwide rollout of ClearTax AI, a multilingual AI-powered personal tax assistant, with full regional languages including Kannada support.

see more..

Samsung is set to launch its seventh-generation series of foldable devices

09 Jul 2025 | 4:34 PM

New Delhi, July 9 (UNI) In a much-anticipated tech move, today Samsung is introducing its seventh-generation series of foldable devices, including Galaxy Z Fold 7, Galaxy Z Flip 7, and Galaxy Flip 7 FE. The launch event will happen in Brooklyn, New York, and the live streaming will take place on Samsung Newsroom India and Samsung India's YouTube channel.

see more..